Ikarian Capital
Ikarian Capital reported 125 stocks worth $504M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (10.0%), ABVX (5.6%) and PCVX (4.5%). Compared with Q2 2026, the fund opened new positions in ORIC, DMRA and FRNM, added to PCVX, RCUS and CLDX, trimmed KOD, ABVX and ANIP and sold out of HIMS, RARE and BIOA.
Latest filing: what Ikarian Capital did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KOD Kodiak Sciences Inc | $50.5M | 10.0% | 533K | −527K (−50%) | 8 of 8 | |
| 2 | ![]() ABVX Abivax SA | $28.4M | 5.6% | 286K | −43K (−13%) | 5 of 8 | |
| 3 | ![]() PCVX Vaxcyte Inc | $22.8M | 4.5% | 400K | +12K (+3%) | 7 of 8 | |
| 4 | ![]() RCUS Arcus Biosciences Inc | $19M | 3.8% | 735K | +230K (+46%) | 5 of 8 | |
| 5 | ![]() CLDX Celldex Therapeutics Inc | $16.8M | 3.3% | 519K | +40K (+8%) | 3 of 8 | |
| 6 | ![]() AMLX Amylyx Pharmaceuticals Inc | $16.3M | 3.2% | 561K | +444K (+378%) | 3 of 8 | |
| 7 | ![]() PHVS Pharvaris N V | $15.9M | 3.2% | 502K | +194K (+63%) | 5 of 8 | |
| 8 | ![]() VERA Vera Therapeutics Inc | $12.9M | 2.6% | 400K | +90K (+29%) | 4 of 8 | |
| 9 | ![]() ANRO Alto Neuroscience Inc | $12.3M | 2.4% | 482K | +75K (+18%) | 8 of 8 | |
| 10 | ![]() COGT Cogent Biosciences Inc | $11.9M | 2.4% | 370K | No change | 4 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
GALECTO INC | $8.7M | 336K |
![]() HIMS Hims & Hers Health Inc | $6.5M | 188K |
![]() RARE Ultragenyx Pharmaceutical in | $5.5M | 166K |
![]() BIOA Bioage Labs Inc | $4.9M | 200K |
![]() BBIO Bridgebio Pharma Inc | $4.3M | 57K |
🔒 Free account: see all 20.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() MRNA Moderna Inc | Put | $77M | 400K | 0 |
![]() BMY Bristol Myers Squibb Co | Put | $61.9M | 993K | +950,000 |
![]() XBI Spdr Series Trust | Put | $47.3M | 300K | 0 |
![]() PRAX Praxis Precision Medicines I | Call | $29.1M | 100K | +79,800 |
![]() IRON Disc Medicine Inc | Put | $25.5M | 389K | +375,800 |
🔒 Free account: see all 20.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Ikarian Capital 13F FAQ
What does Ikarian Capital own?
Ikarian Capital reported 125 stocks worth $504M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (10.0%), ABVX (5.6%) and PCVX (4.5%). The table above lists every position in the filing (the top 10 without an account).
What did Ikarian Capital buy and sell in Q3 2026?
Compared with Q2 2026: 19 new positions, 21 added to, 31 trimmed and 20 sold out. New positions include ORIC, DMRA and FRNM. It sold all of HIMS, RARE and BIOA.
When will Ikarian Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Ikarian Capital's portfolio worth?
The Q3 2026 filing reports $504M in US stocks ($994M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.



























